Bristol-Myers Squibb posted Q2 revenue of $12.97 billion, beating analyst consensus by $1.23 billion, and reported non-GAAP EPS of $2.04 against an expected $1.60. Newer drugs Camzyos and Reblozyl, alongside blood thinner Eliquis, drove the outperformance. The company raised its full-year financial outlook on the back of those results.
A $1.23 billion revenue beat with a raised full-year guide signals that BMS's newer drug portfolio is offsetting declines in older franchises like Opdivo and Pomalyst faster than the market priced in. For healthcare ETF holders, this lifts the sector's near-term earnings narrative. Investors in BMS directly should watch whether Camzyos and Reblozyl can sustain this growth rate, since the older drugs losing ground represent a structural headwind.
BMS Q3 2025 earnings report, expected late October 2025. FDA decision calendar for Camzyos label expansion, ongoing. Next healthcare sector CPI subcomponent, August 12 CPI release.
Full analysis · Subscribers
The deep dive (bull case, bear case, and the data point that decides which side wins), the cause-and-effect chain behind the move, plain-English explainers for every block.
Aggregated reads dozens of sources in five languages and turns the day into plain-English cards like this one.
Educational analysis of public information, not investment advice. Report an error · Corrections policy
← Today's brief